Pathway / Off-pathway / systemic markers

Klotho

KLprotein

Klotho modulates FGF23-driven myocardial processes and serves as a diagnostic biomarker for myocardial infarction via systemic mineral-metabolism pathways.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencemedium

RationaleFGF23 co-receptor; systemic cardioprotective axis off-pathway.

Druggability

Not assessed (no mapped human gene target).

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)

Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.
Journal of the American Heart Association · 2026 · PMID 41676927 · doi
Diagnostic potential of increased Klotho and FGF23 protein concentrations after myocardial infarction in patients with acute coronary syndrome.
Cardiology journal · 2025 · PMID 40417994 · doi